BVBLUE is a rapid point-of-care diagnostic test designed to support the detection of bacterial vaginosis (BV) in clinical and near-patient settings. Built for use in women’s health programs, outpatient clinics, physician offices, sexual health services, and laboratory support environments, BVBLUE offers a practical solution for providers seeking faster diagnostic insight and improved clinical workflow. 

Bacterial vaginosis is one of the most common vaginal conditions affecting women of reproductive age and is associated with important reproductive and gynecologic health concerns, including increased susceptibility to infection and complications in pregnancy if left undiagnosed or untreated. BVBLUE helps address the need for more accessible, efficient diagnostic support by providing a simple testing option that can be incorporated into routine women’s health assessment and care pathways. 

The product is well suited for healthcare organizations, public health initiatives, reproductive health programs, and commercial distribution partners looking to expand access to reliable point-of-care diagnostic solutions. Its streamlined format supports use in both established healthcare facilities and resource-conscious environments where practical, easy-to-deploy testing tools are essential. 

As part of Clovis Davis Pharmaceuticals & Diagnostics’ women’s health portfolio, BVBLUE represents a focused diagnostic offering intended to support earlier identification, more informed treatment decisions, and stronger healthcare delivery across a range of markets. 

HPG80 is a diagnostic solution designed to support timely screening and clinical decision-making in healthcare settings where accessible, practical testing tools are essential. Developed for use across a variety of care environments, HPG80 is positioned as a point-of-care product that helps providers and healthcare programs strengthen diagnostic efficiency while supporting improved patient management. 

In many healthcare systems, the need for rapid, easy-to-use diagnostic products continues to grow—particularly in environments where faster answers can support better triage, referral, treatment planning, and patient follow-up. HPG80 is intended to meet that need by offering a diagnostic option suitable for routine clinical workflows, outreach programs, and broader screening initiatives. 

The product is particularly relevant for organizations seeking dependable diagnostic tools that can be deployed in both public and private healthcare systems. This includes hospitals, clinics, laboratory networks, health programs, and regional distribution partners working to improve access to modern diagnostic technologies in their target markets. 

As part of Clovis Davis Pharmaceuticals & Diagnostics’ broader diagnostic portfolio, HPG80 reflects a commitment to expanding access to practical, commercially viable healthcare solutions that can be adapted to local market needs and healthcare delivery models. 

Kwiq Test HIV 1/2 is a rapid diagnostic test designed for the qualitative detection of HIV-1 and HIV-2 antibodies in whole blood, serum, or plasma, providing healthcare professionals with a practical and efficient tool for use in screening and diagnostic workflows. Manufactured by Microhaem Scientifics in Uganda and distributed by Clovis Davis Pharmaceuticals & Diagnostics, the product is developed to support HIV testing efforts across clinical, public health, NGO, and community-based healthcare environments. 

Designed for point-of-care use, Kwiq Test HIV 1/2 delivers results in approximately 15–30 minutes, making it suitable for settings where rapid turnaround is critical for counseling, referral, treatment linkage, and same-visit decision-making. Its format supports deployment in hospitals, clinics, outreach programs, laboratories, and decentralized care environments where accessible and easy-to-use diagnostics are needed. 

The test is built to support a broad range of healthcare initiatives, including routine screening, donor-funded HIV programs, public health campaigns, and private-sector diagnostic services. With a 24-month shelf life and storage conditions of 2–30°C, it is well suited for use in diverse operating environments, including regions where robust and field-practical diagnostics are especially important. 

As a product manufactured in Africa and distributed regionally through Clovis Davis Pharmaceuticals & Diagnostics, Kwiq Test HIV 1/2 also reflects a growing emphasis on strengthening local diagnostic manufacturing capacity and improving access to high-quality healthcare solutions across African markets. It is intended for partners seeking scalable, commercially viable, and program-ready HIV diagnostic tools.

Pf-Xpat Malaria is a rapid diagnostic test developed for the detection of Plasmodium falciparum malaria antigens in human blood specimens, supporting faster clinical screening and diagnostic decision-making in malaria-endemic settings. Manufactured by Microhaem Scientifics in Uganda and distributed by Clovis Davis Pharmaceuticals & Diagnostics, the product is designed to meet the needs of healthcare providers, public health programs, and commercial partners seeking practical, high-utility malaria diagnostics. 

The test utilizes a rapid lateral flow immunoassay format and is designed for use with fingerstick or venous whole blood, as well as other applicable specimen types, making it suitable for both facility-based and decentralized healthcare environments. With a turnaround time of approximately 15–30 minutes, Pf-Xpat supports timely screening in outpatient clinics, hospitals, laboratories, community health programs, and field-based healthcare initiatives. 

One of Pf-Xpat’s key advantages is its practical fit for challenging operating environments. The product is designed for storage at 1–40°C and offers a 24-month shelf life, helping support use in tropical and resource-variable settings where cold-chain dependence and limited infrastructure can create barriers to access. 

Pf-Xpat is well positioned for partners working across government health systems, NGO programs, donor-funded malaria initiatives, private healthcare networks, and regional distribution channels. As part of Clovis Davis Pharmaceuticals & Diagnostics’ broader mission to expand access to essential diagnostics, Pf-Xpat contributes to efforts aimed at strengthening malaria screening capacity and improving healthcare responsiveness in affected regions.

MicroScreen Sickle Cell is a rapid diagnostic test designed to support the detection of key hemoglobin variants associated with sickle cell disorders, providing a practical point-of-care solution for screening and diagnostic use in healthcare settings. Manufactured by Microhaem Scientifics in Uganda and distributed by Clovis Davis Pharmaceuticals & Diagnostics, the product is intended to help expand access to faster and more accessible sickle cell testing across clinical and public health environments. 

MicroScreen is designed for use with whole blood samples, including fingerstick collection, and delivers results in approximately 10 minutes, making it well suited for use in hospitals, maternity settings, pediatric care environments, screening programs, community health initiatives, and other healthcare delivery settings where rapid results can improve patient pathway decisions. 

The product supports a range of potential use cases, including newborn screening, antenatal screening, symptomatic testing, genetic counseling support, and broader public health screening efforts. This makes it particularly relevant for healthcare organizations, ministries of health, NGOs, and implementation partners focused on earlier detection and improved patient management in populations affected by sickle cell disease and hemoglobinopathies. 

With a 24-month shelf life and storage range of 2–30°C, MicroScreen is built for practical deployment across a variety of healthcare settings, including environments where simple workflow integration and operational flexibility are important. As a locally manufactured African diagnostic product, it also aligns with broader efforts to improve regional access to quality healthcare technologies and strengthen local health system capacity.